Biotech Company Leverages AI to Combat Early MS Treatment

A biotech company implemented an AI-powered solution to combat high early discontinuation rates for its multiple sclerosis (MS) treatment. The AI solution identified patients at high risk of discontinuation with 81% accuracy and predicted with 100% accuracy who would continue treatment.

Problem Statement:

A large biotech company faced:
● High MS treatment drop-off: Patients stopped taking their immunosuppressant medication early.
● Mystery behind early discontinuation: They lacked understanding of why patients weren’t completing treatment.
● Need for personalized risk assessment: The company needed to identify patients most likely to stop treatment early.

Results:

☑️ 81% accuracy of prognosis of patients who may stop treatment early
☑️ Enhanced understanding of early discontinuation drivers, informing future intervention strategies.

AI Solution:

The company implemented AI by IQVIA to analyze real-world data, identify factors causing early discontinuation, and flag high-risk patients.

The AI achieved impressive accuracy, identifying 81% of patients who stopped treatment early and perfectly predicting those who continued.

Benefits:
● Personalized Interventions: The company can tailor support like medication adherence programs or additional services by understanding why patients might stop treatment (side effects, logistical challenges).
●Improved Adherence: The AI identifies patients who struggle with medication schedules, allowing the company to develop targeted programs, such as reminders or simplified schedules, to improve adherence.
● Increased Efficacy: When patients stay on track, medication works more effectively, reducing MS symptoms and improving quality of life.
● Reduced Costs: Preventing early discontinuation and improving adherence significantly lowers healthcare costs by minimizing hospitalizations and the need for alternative treatments.

References:

1. Predictive Models Improve Patient Adherence for a Large Biotechnology Company

Industry: Healthcare, Pharmaceutical
Vendor: IQVIA
Client: a biotech company